Package Leaflet: Information for the User
Puregon 150UI/0.18ml solution for injection
Puregon 300UI/0.36ml solution for injection
Puregon 600UI/0.72ml solution for injection
Puregon 900UI/1.08ml solution for injection
Follitropin beta
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Puregon solution for injection contains follitropin beta, a hormone known as follicle-stimulating hormone (FSH).
FSH belongs to the group of gonadotropins, which play an important role in human fertility and reproduction. In women, FSH is necessary for the growth and development of follicles in the ovaries. The follicles are small, rounded sacs that contain the eggs. In men, FSH is necessary for sperm production.
Puregon is used to treat infertility in the following situations:
Women
In women who do not ovulate and do not respond to treatment with clomiphene citrate, Puregon can be used to induce ovulation.
In women undergoing assisted reproduction techniques, such as in vitro fertilization (IVF) and other methods, Puregon can produce the development of multiple follicles.
Men
In infertile men due to low hormone levels, Puregon can be used to produce sperm.
Do not use Puregon
If:
Warnings and precautions
Consult your doctor before starting treatment with Puregon if:
If you are a woman:
Ovarian Hyperstimulation Syndrome (OHSS)
Your doctor will regularly check the effects of treatment to choose the right dose of Puregon at each stage. You will have regular ultrasound scans of your ovaries. Your doctor may also check your hormone levels in your blood. This is very important because too high a dose of FSH can lead to rare but serious complications, in which the ovaries become overstimulated and the growing follicles become larger than normal. This disease is serious and is called Ovarian Hyperstimulation Syndrome (OHSS). In rare cases, severe OHSS can be life-threatening. OHSS causes fluid to build up suddenly in your stomach and chest, which can cause blood clots. Contact your doctor immediately if you feel severe abdominal swelling, stomach pain, nausea, vomiting, sudden weight gain due to fluid buildup, diarrhea, decreased urine output, or difficulty breathing (see also section 4, Possible side effects).
? Regular monitoring of your response to FSH treatment helps prevent ovarian overstimulation. Contact your doctor immediately if you feel stomach pain, and also if it occurs a few days after the last injection.
Multiple Pregnancy or Birth Defects
After treatment with gonadotropins, there is a higher chance of multiple pregnancies, even when only one embryo is transferred to the uterus. Multiple pregnancies pose an increased risk to the health of both the mother and the children before and after birth. Additionally, multiple pregnancy and the characteristics of patients undergoing fertility treatment (e.g., woman's age, semen characteristics, genetic history of both parents) may be associated with a higher risk of birth defects.
Pregnancy Complications
The risk of an ectopic pregnancy (a pregnancy outside the uterus) is slightly higher. Therefore, your doctor should perform an ultrasound at the beginning to rule out the possibility of an ectopic pregnancy.
In women undergoing fertility treatment, there is a slightly higher risk of miscarriage.
Blood Clots (Thrombosis)
Treatment with Puregon, like pregnancy itself, can increase the risk of blood clots (thrombosis). Thrombosis is the formation of a blood clot in a blood vessel.
Blood clots can cause serious diseases, such as:
Discuss this with your doctor before starting treatment, especially in the following cases:
Ovarian Torsion
Torsion can occur after treatment with gonadotropins, including Puregon. Ovarian torsion is the twisting of an ovary. The twisting of the ovary could cause the blood flow to the ovary to be cut off.
Before starting treatment with this medicine, tell your doctor if:
Ovarian Tumors and Other Reproductive System Tumors
Cases of ovarian tumors and other reproductive system tumors have been reported in women who have undergone fertility treatment. It is not known if treatment with fertility medications increases the risk of these tumors in infertile women.
Other Diseases
Additionally, before starting treatment with this medicine, tell your doctor if:
If you are a man:
Men with High FSH Levels in the Blood
High FSH levels in the blood are a sign of testicular damage. In such cases, Puregon is usually not effective. To monitor the effects of treatment, your doctor may ask for a semen sample to analyze, 4 to 6 months after starting treatment.
Children and Adolescents
Puregon should not be used in children and adolescents.
Using Puregon with Other Medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
If Puregon is given with clomiphene citrate, the effect of Puregon may be increased. If a GnRH agonist (a medicine to prevent early ovulation) has been given, higher doses of Puregon may be needed.
Pregnancy and Breast-feeding
Ask your doctor or pharmacist for advice before taking any medicine. You should not use Puregon if you are already pregnant or think you may be pregnant.
Puregon may affect milk production. It is unlikely that Puregon will pass into breast milk. If you are breast-feeding, ask your doctor for advice before using Puregon.
Driving and Using Machines
Puregon is unlikely to affect your ability to drive or use machines.
Puregon Contains Benzyl Alcohol
This medicine contains 10 mg of benzyl alcohol per ml.
Benzyl alcohol may cause allergic reactions.
Ask your doctor or pharmacist for advice if you have liver or kidney disease. This is because large amounts of benzyl alcohol can build up in the body and cause side effects (metabolic acidosis).
Ask your doctor or pharmacist for advice if you are pregnant or breast-feeding. This is because large amounts of benzyl alcohol can build up in the body and cause side effects (metabolic acidosis).
Puregon Contains Sodium
This medicine contains less than 1 mmol of sodium (23 mg) per injection; this is essentially "sodium-free".
Follow the instructions for administration of this medicine exactly as told by your doctor. If you are not sure, ask your doctor or pharmacist again.
Dosing in Women
Your doctor will decide the initial dose. This dose may be adjusted as your treatment progresses. More details on the dosing schedule are provided below.
There are large variations in ovarian response to FSH among women, making it impossible to establish a suitable dosing schedule for all patients. To find the correct dosage, your doctor will monitor follicle growth with ultrasound and measure estradiol (female sex hormone) levels in your blood.
Dosing in Men
Puregon is usually prescribed at a dose of 450 UI per week, almost always in three injections of 150 UI, along with another hormone (hCG), for at least 3 to 4 months. The treatment period is equal to the time needed for sperm development and the expected time for improvement. If your sperm production has not started after this period, your treatment may continue for at least 18 months.
How to Administer the Injection
Puregon solution for injection in cartridges has been developed for use with the Puregon Pen injection device. The instructions for using the injection device, which are provided separately, must be followed carefully. Do not use the cartridge if the solution contains particles or is not clear.
With the injection device, injections under the skin (e.g., in the lower abdomen) can be administered by you or your partner. Your doctor will tell you when and how to do this. If you inject Puregon yourself, follow the instructions for administration carefully and with minimal discomfort.
The first injection of Puregon should only be administered in the presence of a doctor or nurse.
It is possible that a small amount of medicine will remain in the cartridge after completing treatment with Puregon, even when all doses have been administered correctly. Do not attempt to use the remaining medicine. After administration of the last dose, the cartridge should be disposed of properly.
If You Use More Puregon than You Should
Tell your doctor immediately.
Taking too high a dose of Puregon can cause excessive stimulation of the ovaries (OHSS), which can manifest as stomach pain. If you feel unwell due to stomach pain, tell your doctor immediately. See also section 4, Possible side effects.
If You Forget to Use Puregon
If you miss a dose, do not take a double dose to make up for the missed doses.
? Contact your doctor.
If you have any further questions on the use of this medicine, ask your doctor.
Like all medicines, this medicine may cause adverse effects, although not all people suffer from them.
Inform your doctor immediately if you notice:
Signs of a severe allergic reaction (anaphylactic reaction), such as swelling of the face, lips, throat, or tongue that cause difficulty swallowing or breathing, shortness of breath, feeling of loss of consciousness.
Severe Adverse Effects in Women
A complication of FSH is ovarian hyperstimulation. Ovarian overstimulation can trigger a disease called Ovarian Hyperstimulation Syndrome (OHSS), which can be a serious clinical problem. The risk of this occurring can be reduced by carefully controlling follicle development during treatment. Your doctor will perform ultrasound scans of your ovaries to carefully monitor the number of mature follicles. Your doctor may also check hormone levels in your blood. The first symptoms are stomach pain, discomfort, or diarrhea. In more severe cases, you may experience enlargement of the ovaries, fluid accumulation in the abdomen and/or chest, (which can cause sudden weight gain due to fluid accumulation) or the formation of blood clots in the circulatory system. See section 2 Warnings and Precautions.
If you experience stomach pain or any of these symptoms of ovarian hyperstimulation, contact your doctor immediately, even if they occur several days after the last injection.
If you are a woman:
Adverse Effectsfrequently (may affect up to1in every10 people):
and itching)
Adverse Effectsinfrequently (may affect up to1 in every100 people):
Adverse Effectsrarely(may affect up to1 in every1,000 people):
Frequency not known (cannot be estimated from the available data):
Ectopic pregnancies, spontaneous abortions, and multiple pregnancies have also been reported. These adverse effects are not considered related to the use of Puregon, but to Assisted Reproduction Techniques (ART) or a subsequent pregnancy.
If you are a man:
Adverse Effectsfrequently (may affect up to1in every10 people):
Frequency not known (cannot be estimated from the available data):
Reporting of Adverse Effects
If you experience any adverse effects, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Storage by the pharmacist
Store between 2°C - 8°C (in the refrigerator). Do not freeze.
Storage by the patient
You have two options:
Write down the day you start storing the product outside the refrigerator.
Keep the cartridge in the outer packaging.
Once the rubber membrane of the cartridge is pierced with a needle, the product can be stored for 28 days, maximum.
Please write down the first day of use of the cartridge in the control table, as shown in the Puregon Pen Instructions for Use.
Do not use this medicine after the expiration date stated on the packaging after 'EXP'. The expiration date is the last day of the month indicated.
Discard used needles immediately after injection.
Do not mix any other medicine in the cartridges. Do not refill empty cartridges.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Puregon Composition
Appearance of the Product and Package Contents
Puregon injectable solution (injectable) is a clear, colorless liquid, presented in a glass cartridge. It is available in packs of 1 cartridge.
Marketing Authorization Holder and Manufacturer
N.V. Organon
Kloosterstraat 6
5349 AB Oss
Netherlands
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Belgium Organon Belgium Tel: 0080066550123 (+32 2 2418100) dpoc.benelux@organon.com | Lithuania Organon Pharma B.V. Lithuania branch Tel.: +370 52041693 dpoc.lithuania@organon.com |
Bulgaria Organon Bulgaria EOOD Tel: +359 2 806 3030 dpoc.bulgaria@organon.com | Luxembourg Organon Belgium Tel: 0080066550123 (+32 2 2418100) dpoc.benelux@organon.com |
Czech Republic Organon Czech Republic s.r.o. Tel: +420 233 010 300 dpoc.czech@organon.com | Hungary Organon Hungary Kft. Tel.: +36 1 766 1963 dpoc.hungary@organon.com |
Denmark Organon Denmark ApS Tel: +45 4484 6800 info.denmark@organon.com | Malta Organon Pharma B.V., Cyprus branch Tel: +356 2277 8116 dpoc.cyprus@organon.com |
Germany Organon Healthcare GmbH Tel.: 0800 3384 726 (+49 (0) 89 2040022 10) dpoc.germany@organon.com | Netherlands N.V. Organon Tel: 00800 66550123 (+32 2 2418100) dpoc.benelux@organon.com |
Estonia Organon Pharma B.V. Estonian branch Tel: +372 66 61 300 dpoc.estonia@organon.com | Norway Organon Norway AS Tel: +47 24 14 56 60 info.norway@organon.com |
Greece BIANEΞ Α.Ε. Tel: +30 210 80091 11 Mailbox@vianex.gr | Austria Organon Healthcare GmbH Tel: +49 (0) 89 2040022 10 dpoc.austria@organon.com |
Spain Organon Salud, S.L. Tel: +34 91 591 12 79 organon_info@organon.com | Poland Organon Polska Sp. z o.o. Tel.: +48 22 105 50 01 organonpolska@organon.com |
France Organon France Tel: +33 (0) 1 57 77 32 00 | Portugal Organon Portugal, Sociedade Unipessoal Lda. Tel: +351 218705500 geral_pt@organon.com |
Croatia Organon Pharma d.o.o. Tel: +385 1 638 4530 dpoc.croatia@organon.com | Romania Organon Biosciences S.R.L. Tel: +40 21 527 29 90 dpoc.romania@organon.com |
Ireland Organon Pharma (Ireland) Limited Tel: +353 15828260 medinfo.ROI@organon.com | Slovenia Organon Pharma B.V., Oss, Ljubljana branch Tel: +386 1 300 10 80 dpoc.slovenia@organon.com |
Iceland Vistor hf. Tel: +354 535 7000 | Slovakia Organon Slovakia s.r.o. Tel: +421 2 44 88 98 88 dpoc.slovakia@organon.com |
Italy Organon Italia S.r.l. Tel: +39 06 90259059 dpoc.italy@organon.com | Finland Organon Finland Oy Tel: +358 (0) 29 170 3520 dpoc.finland@organon.com |
Cyprus Organon Pharma B.V., Cyprus branch Tel: +357 22866730 dpoc.cyprus@organon.com | Sweden Organon Sweden AB Tel: +46 8 502 597 00 dpoc.sweden@organon.com |
Latvia Organon Pharma B.V. branch office Tel: +371 66968876 dpoc.latvia@organon.com | United Kingdom (Northern Ireland) Organon Pharma (UK) Limited Tel: +44 (0) 208 159 3593 medicalinformationuk@organon.com |
Date of the last revision of this leaflet:month YYYY
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website https://www.ema.europa.eu.